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Angioimmunoblastic T-cell lymphoma is the most
common T-cell lymphoma in two distinct French 
information data sets
Reliable information regarding the current prevalence of
peripheral T-cell lymphoma (PTCL) entities is missing.
Herein we report on the frequency of PTCL entities in
France between 2010 and 2013. Using Lymphopath, a
national lymphoma network established by the French
National Cancer Agency, which covers about 70 % of all
lymphomas currently diagnosed in France, we found that
PTCL comprised 6.5 % of non-cutaneous lymphomas with
angioimmunoblastic T-cell lymphoma (AITL) being the
most frequent (739 cases; 36 %), followed by peripheral T-
cell lymphoma not otherwise specified (PTCL-NOS) (550
cases, 27%). These data were verified in an independent
data set from a transnational research consortium active in
three European countries. In comparison to epidemiologic
data reported previously, we show that AITL is by far the
most common PTCL subtype. In light of the results of
recent molecular findings highlighting the heterogeneity of
T-cell lymphomas and the advent of targeted therapies,
these data have important implications for both basic and
clinical research.
Peripheral T-cell lymphomas (PTCLs) represent diverse
and complex diseases, estimated to represent an overall 10-
15% of all lymphomas worldwide, with the highest inci-
dence rates occurring in Asia.1,2 The relative prevalence of
PTCL entities delineated according to the criteria of the
REAL (1994) /WHO (2001) classification systems, was eval-
uated in multiple institutions in the late 1990s and early
2000s, based on retrospective cohorts of patients. In those
series, PTCL-NOS (a “by default” diagnosis for cases not ful-
filling the criteria for other more specific entities) was the
most frequent entity, followed by anaplastic large cell lym-
phoma (ALCL) and AITL, while extranodal entities, in gen-
eral, accounted for a small proportion of the cases.1,3,4 
This worldwide epidemiology was most recently
addressed by the International PTCL study, which reviewed
more than 1,300 patients diagnosed with PTCL between
1990 and 2002 in North America, Europe and Asia.5 In this
cohort, PTCL-NOS was the most common diagnosis
(25,9%), followed by AITL (18,5%), representing 30.4%
and 21.7% of non-cutaneous PTCL, respectively (Figure 1).5
This study also confirmed geographic variations in the dis-
tribution of PTCL entities, notably demonstrating that the
highest frequencies of AITL and enteropathy-associated T-
cell lymphoma (EATL) are in Europe. 
Here, we provide recent data obtained from a large
prospective survey in France. The prevalent analysis of
PTCL was derived from data collected through Lymphopath,
a national network of 33 expert reference centers for
hematopathology which was established by the French
National Cancer Agency in 2010. Non-expert pathologists
are encouraged to refer every newly diagnosed lymphoma
for review to a Lymphopath center.  Diagnoses provided by
experts, following slide review and additional ancillary tech-
niques performed in the reference center, are entered into a
central database. Of the 31,401 non-cutaneous lymphomas
reviewed in Lymphopath over four years (2010-2013), there
were 2,046 cases of PTCLs (6.5%) which comprised: 739
AITL (36.1%), 550 PTCL-NOS (26.9%), 176 ALK+ ALCL
(8.6%), 162 ALK- ALCL (7.9%), 107 extranodal NK/T-cell
lymphomas, nasal-type (5.2%), 77 EATL (3.8%), 52 adult T-
cell leukemia/lymphoma (2.5%) and 20 hepatosplenic T-cell
lymphomas (1.0%). The remaining 163 cases (8%) included
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Figure 1. Relative frequency of non-cutaneous PTCL entities according to the International peripheral T-cell lymphoma (PTCL) project
(worldwide (n=1314) and European (n=450) statistics)5 and in the Lymphopath registry (France) (n=2046). ALCL: anaplastic large cell lym-
phoma; ALK: anaplastic lymphoma kinase; ATLL: adult T-cell leukemia/lymphoma; EATL: enteropathy-associated T-cell lymphoma; HSTL:
hepatosplenic T-cell lymphoma; NK/T: extranodal NK/T-cell lymphoma; PTCL-NOS: peripheral T-cell lymphoma, not otherwise specified.
For the International T-cell lymphoma project, the percentage of the different non-cutaneous PTCL entities have been adjusted, after
exclusion of cases not confirmed to be T-cell lymphomas (for the international statistics) and exclusion of categories corresponding to
cutaneous lymphomas and “other disorders”.  
74 cases of NK/T-cell leukemias (15 aggressive NK-cell
leukemias, 14 T-prolymphocytic leukemias and 45 large
granular lymphocyte leukemias), and 89 other, or unclassi-
fiable cases. Thus, in Lymphopath, AITL represents the most
frequent non-cutaneous PTCL entity (36.1%) followed by
PTCL-NOS (26.9%), which is distinctly less recurrent. 
In comparison to the European data of the International
PTCL study (Figure 1), the current findings differ principally
with respect to the relative prevalence of AITL and PTCL-
NOS.5 The reason for this discrepancy is unclear. The inter-
national study comprised a total of 450 European cases col-
lected from eight submitting centers (two centers from
Spain and Italy, and one center each from France, Germany,
UK, and Norway), whereas the current analysis encompass-
es a much higher number of cases, estimated to be com-
prised of more than 70% of all new lymphoma diagnoses in
France. Yet, despite the coverage not being exhaustive, it
thus far represents the most recent and largest prospectively
collected series validated by expert hematopathologists,
with unrestricted access to ancillary diagnostic tools.
Although a selection bias inherent to the design of the
international study (retrospective collection, limited number
of submitting centers, university medical centers only) can-
not be excluded, the differences observed may in fact reflect
geographical differences within Europe. An overrepresenta-
tion of EATL in Nordic countries is well recognized, but this
largely rare disease has only minimal impact on global sta-
tistics. Interestingly, according to the data collected by the
national Swedish Lymphoma Registry over a 10-year period
(2000-2009), the 755 PTCL (non-cutaneous and non-
leukemic) registered in Sweden comprised 34% PTCL-
NOS, 29% ALCL, only 14% AITL, and 9% EATL, a distri-
bution also markedly different from both the published
European statistics and from our findings, thus further sug-
gesting geographic variations.6 
Another potentially conflicting difference is that the inter-
national study cohort comprises cases diagnosed between
1990 and 2002 and reviewed with reference to the 2001
WHO classification, while the Lymphopath dataset is derived
from a more recent observation period (2010-2013). In the
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Table 1. Clinical characteristics of 246 AITL patients with follow-up data from the Tenomic collection with comparison with other published
series.
Mourad Lachenal Tokunaga Federico TENOMIC
Blood 20087 Medicine 20078 Blood 20129 JCO 201210
Time period for case collection 1987-2008 1990-2004 1990-2008 1990-2002 1999-2009
GELA Lyon Japan International T-cell France, Belgium, 
project Switzerland
N. 157 77 207 243 246
Median age 62 64 67 65 66
(year) [range] [20-89] [30–91] [34-91] [20-86] [27-92]
Male to female ratio 1.5:1 1.26:1 1.8:1 1.3:1 1.5:1
B symptoms 72% 77% 60% 69% 64% 
(112/155) (59/77) (122/202) (168/202) (139/217)
Stage III - IV 81% 92% 90% 89% 98% 
(126/156) (71/77) (186/207) (214/241) (235/240)
Bone marrow involvement 47% 60% 29% 28% 42%
(71/151) (NA) (59/202) (67/228) (91/218)
Splenomegaly 55% 51% NA 35% 26%
(86/155) (39/77) (NA) (56/215)
Hepatomegaly 31% 26% 9% 26% 15%
(38/154) (20/77) (18/192) (NA) (35/230)
Anemia 65%† 51%‡ 61%‡ 33%‡‡ 61%‡
(101/155) (39/76) (126/207) (81/205) (135/220)
Coombs positivity 33% 58% 46% NA 58%
(30/92) (38/66) (29/63) (88/153)
Hypergammaglobulinemia 50% 51% 54% 30% 65%
(73/146)* (37/73)¥ (89/166)¥ (74/166)¥ (102/156)*
LDH >1N 66% 71% 75% 60% 70%
(98/149) (55/77) (154/205) (146/223) (146/208)
IPI score ≥ 2 89% 87% 89% 79% 95%
(117/132) (NA) (175/197) (192/222) (217/229)
PIT score ≥2 74% NA 77% 63% 78%
(106/144) (153/198) (154/233) (167/213)
Median follow-up (months) 69 35,5 42 NA 61,5
3-years survival NA 49% 54% NA 41%
5-years survival 33% NA 41% 32% 34%
‡Hemoglobin<12 gr/dL, ‡Hemoglobin<11.5 gr/dL,  ‡‡undefined Hemoglobin level for anemia, *>12 gr/dL, ¥>16 gr/dL, NA: not available.
interim, it was discovered that AITL is associated to CD10
expression and derived from T follicular helper (TFH) cells.
These perceptions were incorporated into the description of
AITL in the 2008 WHO classification,2 and since then CD10
and novel markers associated to TFH differentiation have
been validated for diagnostic use and increasingly incorpo-
rated into routine practice.7 Thus, consideration must be
given to whether the higher prevalence of AITL observed
recently might be linked in some way to the availability of
novel ancillary tools to support the diagnosis. 
Confronted with the lack of a similar systematic database
antedating Lymphopath in France, we used another non-
overlapping set of PTCL patients to compare the distribu-
tion of PTCL entities over an earlier time period. This set of
patients was collected through Tenomic, a transnational
research consortium on T-cell lymphomas involving several
LYSA (Lymphoma Study Association) centers in France,
Belgium and Switzerland. The Tenomic database (approved
by the ethical committee “CPP Ile-de-France IX 08-009”) is
a retrospective and prospective collection of PTCL samples
with available frozen tissue, and corresponding clinical
annotations (Online Supplementary Methods), including a sub-
set of patients enrolled in GELA/LYSA studies. All Tenomic
cases are reviewed by at least two expert hematopatholo-
gists belonging to the consortium, and classified according
to the 2008 WHO criteria. The Tenomic database comprised
623 non-anaplastic PTCL cases diagnosed between 1999
and 2009, reviewed after 2008. Remarkably, within the lim-
its of this retrospective collection, there was an even higher
ratio of AITL (n=293) to PTCL-NOS (n=171) in the Tenomic
dataset (1.7:1) than in that of Lymphopath (1.35:1).
According to the detailed records available for 236 AITL
cases (Online Supplementary Methods and Online
Supplementary Table S1), the characteristic morphological
features of AITL (polymorphic cellular infiltrate (100%),
arborizing vessels (98%) blast cells (94%), clear cells (69%)
and sinus sign (72%)), were present in most cases. In addi-
tion, an expansion of follicular dendritic cells (FDCs),
regarded as a hallmark of AITL,7was present in 93% of the
cases, and EBV-positive blasts were evidenced in 77%. The
percentages of cases expressing CD10 (83%) and the TFH-
associated molecules PD1 (78%), CXCL13 (76%) and BCL6
(62%) in the neoplastic cells were comparative to those pre-
viously reported.7 In addition, among the 246 patients who
had available follow-up data, the frequencies of B symp-
toms (67%), advanced stage disease (98%), IPI score>2
(94%), hypergammaglobulinemia (64%) and positive
Coombs' test (41%) (Table 1), were overall similar to those
recorded in other series,8-11 providing evidence that the
pathological AITL diagnoses were concordant with the clin-
ical and biological features of that entity. The five-year over-
all survival (OS) for the entire group, whose treatment char-
acteristics are detailed in the Online Supplementary Table
S2, was 34% (IC 95% [27%-40%]) (Online Supplementary
Figure S1), which is also in agreement with other series.8-11
Interestingly, 43 of the 293 Tenomic AITL cases (14.6%)
had initially been  diagnosed as PTCL-NOS, and reclassified
as AITL cases by expert review. The pathological and clini-
cal features (shown in Online Supplementary Tables S3 and
S4) of these reclassified cases did not differ from those of the
entire cohort, suggesting that the apparent “increase” in
AITL frequency may at least partly reflect the underrecogni-
tion or underdiagnosis of this entity in previous years.
This report further confirms the poor long-term outcome
for AITL patients, and in view of the high prevalence of this
disease there are essential, but as yet unfulfilled, needs for
new therapeutic options. Importantly, the response to novel
agents in AITL patients may be distinctively different from
that seen in other PTCL patients.12 
In that respect, the recent findings of recurrent mutations
in genes coding for enzymes controlling DNA methylation
(TET2, IDH2 and DNMT3),13,14 and in RHOA (coding for a
small GTPase),15 offer rationale for the use of demethylating
agents and/or specific inhibitors in AITL patients.16 As a
whole, the data presented herein are highly relevant at a
time when there is a shift towards the development of indi-
vidualized therapies in PTCL, and should be taken into con-
sideration for the design of future clinical studies.
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